SitemapContact Us
닫기
Search
Advanced Search +
닫기
Quick links
Most Cited Most Read Ahead of Print Archives Go to E-submission

Perspective

Split Viewer

Blood Res 2019; 54(2):

Published online June 30, 2019

https://doi.org/10.5045/br.2019.54.2.81

© The Korean Society of Hematology

Chimeric antigen T cell receptor treatment in hematological malignancies

Natasha Ali, FCPS Haematology

Author Info. +

Department of Pathology and Laboratory Medicine/Oncology, Aga Khan University, Karachi, Pakistan

Correspondence to : Natasha Ali, FCPS Haematology
Department of Pathology and Laboratory Medicine/Oncology, Aga Khan University, Karachi, Pakistan

Received: February 24, 2019; Revised: April 5, 2019; Accepted: April 28, 2019

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

REFERENCES

Go to
  1. Bartenstein M, Deeg HJ. Hematopoietic stem cell transplantation for MDS. Hematol Oncol Clin North Am 2010;24:407-422.
    Pubmed
  2. Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A 1993;90:720-724.
    Pubmed
  3. Sadelain M, Rivière I, Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer 2003;3:35-45.
    Pubmed
  4. Wohlfarth P, Worel N, Hopfinger G. Chimeric antigen receptor TXMLLink_XYZcell therapy-a hematological success story. Memo 2018;11:116-121.
    Pubmed
  5. Locke FL, Ghobadi A, Jacobson CA, et al. Durability of response in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B-cell lymphoma. J Clin Oncol 2018;36:abst 3003.
  6. Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med 2018;378:439-448.
    Pubmed
  7. Mikkilineni L, Kochenderfer JN. Chimeric antigen receptor T-cell therapies for multiple myeloma. Blood 2017;130:2594-2602.
    Pubmed
  8. Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigenreceptor-transduced T cells. Blood 2012;119:2709-2720.
    Pubmed
  9. Bross PF, Beitz J, Chen G, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 2001;7:1490-1496.
    Pubmed
  10. Hills RK, Castaigne S, Appelbaum FR, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol 2014;15:986-996.
    Pubmed
  11. Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol 2018;15:47-62.
    Pubmed
  12. Ataca P, Arslan Ö. Chimeric antigen receptor T cell therapy in hematology. Turk J Haematol 2015;32:285-294.
    Pubmed
  13. Porter DL, Kalos M, Frey NV, et al. Randomized, phase II dose optimization study of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed, refractory CLL. Blood (ASH Annual Meeting Abstracts) 2013;122:abst 873.
  14. Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 2014;6:224ra25.

Article

Perspective

Blood Res 2019; 54(2): 81-83

Published online June 30, 2019 https://doi.org/10.5045/br.2019.54.2.81

Copyright © The Korean Society of Hematology.

Chimeric antigen T cell receptor treatment in hematological malignancies

Natasha Ali, FCPS Haematology

Department of Pathology and Laboratory Medicine/Oncology, Aga Khan University, Karachi, Pakistan

Correspondence to:Natasha Ali, FCPS Haematology
Department of Pathology and Laboratory Medicine/Oncology, Aga Khan University, Karachi, Pakistan

Received: February 24, 2019; Revised: April 5, 2019; Accepted: April 28, 2019

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

    References

    1. Bartenstein M, Deeg HJ. Hematopoietic stem cell transplantation for MDS. Hematol Oncol Clin North Am 2010;24:407-422.
      Pubmed
    2. Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A 1993;90:720-724.
      Pubmed
    3. Sadelain M, Rivière I, Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer 2003;3:35-45.
      Pubmed
    4. Wohlfarth P, Worel N, Hopfinger G. Chimeric antigen receptor TXMLLink_XYZcell therapy-a hematological success story. Memo 2018;11:116-121.
      Pubmed
    5. Locke FL, Ghobadi A, Jacobson CA, et al. Durability of response in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B-cell lymphoma. J Clin Oncol 2018;36:abst 3003.
    6. Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med 2018;378:439-448.
      Pubmed
    7. Mikkilineni L, Kochenderfer JN. Chimeric antigen receptor T-cell therapies for multiple myeloma. Blood 2017;130:2594-2602.
      Pubmed
    8. Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigenreceptor-transduced T cells. Blood 2012;119:2709-2720.
      Pubmed
    9. Bross PF, Beitz J, Chen G, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 2001;7:1490-1496.
      Pubmed
    10. Hills RK, Castaigne S, Appelbaum FR, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol 2014;15:986-996.
      Pubmed
    11. Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol 2018;15:47-62.
      Pubmed
    12. Ataca P, Arslan Ö. Chimeric antigen receptor T cell therapy in hematology. Turk J Haematol 2015;32:285-294.
      Pubmed
    13. Porter DL, Kalos M, Frey NV, et al. Randomized, phase II dose optimization study of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed, refractory CLL. Blood (ASH Annual Meeting Abstracts) 2013;122:abst 873.
    14. Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 2014;6:224ra25.
    Blood Res
    Volume 59 2024
    Current Issue Archives

    Stats or Metrics

    Share this article on

    • line

    Blood Research

    pISSN 2287-979X
    eISSN 2288-0011
    qr-code Download